Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 30;4(1):vdab177. doi: 10.1093/noajnl/vdab177

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 5. — Overview of DNA-based biomarkers and potential treatment options in 42 whole-genome sequenced glioblastoma samples (CPCT-02). (A) Highest level of potential treatment options available based on genomic characteristics. On-Label indicates treatment registered by federal authorities for glioblastoma, whereas Off-Label indicates a registration for other tumor types. (B) The distribution of actionable target types in percentages. (C) Potentially actionable alterations at gene level with every column portraying a sample, ordered descendingly by tumor mutational burden on the x-axis. A tile is colored pink in case of an On-Label treatment and blue for Off-Label.